

ASX RELEASE

15 December 2025

Successful completion of \$30.0 million Placement

Highlights

- Firm commitments received for a Placement of 20.0 million shares at a price of \$1.50 per share to raise \$30.0 million (before costs)
- The Placement was strongly supported by both existing and new professional and sophisticated investors which will help strengthen the institutional ownership of Acusensus and increase the free-float and liquidity in the market for Acusensus shares
- Proceeds from the Placement will be applied to business development, contract mobilisation and purchase of fixed assets, product innovation, working capital, litigation related costs and costs of the Placement

Acusensus Limited (ASX:ACE) (**Acusensus** or the **Company**), a technology company designing and developing artificial intelligence enabled road safety solutions, is pleased to announce it has received binding commitments for a \$30.0 million placement to existing and new professional and sophisticated investors through the issue of 20.0 million new fully paid ordinary shares (**New Shares**) (**Placement**). New Shares issued in the Placement will be issued utilising Acusensus' existing Placement capacity under ASX Listing Rule 7.1 and 7.1A and represent approximately 14.1% of existing shares on issue.

New Shares in the Placement will be issued at \$1.50 per New Share (**Offer Price**), which represents a:

- 9.1% discount to the last close price of \$1.65 per share;¹
- 8.5% discount to 5-day VWAP² of \$1.64 per share; and
- 11.9% discount to 15-day VWAP³ of \$1.70 per share.

Proceeds from the Placement will be applied to business development, contract mobilisation and purchase of fixed assets, product innovation, working capital, litigation related costs and costs of the Placement.

Acusensus Founder and Managing Director, Alexander Jannink, said:

"I am delighted by the very strong support we have received one again from existing shareholders and new investors to advance our mission to reduce road casualties on a global basis. This placement broadens our shareholder register, promotes liquidity, accelerates our growth strategy and strengthens our ability to submit for more work on a global scale. I am

¹ Closing price on 11 December 2025.

² Volume Weighted Average Price (VWAP) from 5 December 2025 to 11 December 2025 (inclusive).

³ Volume Weighted Average Price (VWAP) from 21 November 2025 to 11 December 2025 (inclusive).

excited by the breadth of opportunities in front of us and I thank our employees, shareholders and partners for their continued support of our goals.”

Acusensus will resume trading on the ASX from market open today, 15 December 2025. The New Shares issued under the Placement are expected to settle on Friday, 19 December 2025 and be issued and commence trading on the ASX on a normal settlement basis on Monday, 22 December 2025. New Shares issued under the Placement will rank equally with the Company’s existing shares on issue.

Morgans Corporate Limited and Canaccord Genuity (Australia) Limited acted as Joint Lead Managers to the Placement. Fees associated with the Placement include the following percentages of the gross proceeds of the Placement:

- a combined selling fee of 3.7%, with 50% paid to each Joint Lead Manager;
- a discretionary fee of 0.5%, which is subject to certain conditions and payable at the discretion of the Company, including as to the proportions paid to each Joint Lead Manager; and
- a management fee of 0.3% paid to Morgans Corporate Limited.

Timetable⁴

Event	Dates (AEDT)
Trading halt and bookbuild	Friday, 12 December 2025
Announcement of completion of Placement	Monday, 15 December 2025
Settlement of New Shares under the Placement	Friday, 19 December 2025
Allotment, quotation and trading of New Shares under the Placement	Monday, 22 December 2025

Additional information

Further details of the Placement are set out in the Investor Presentation provided to the ASX as a separate announcement today. The Investor Presentation sets out important risks and disclaimers in respect of the Placement.

END

Enquiries

Anita Chow
Chief Financial Officer, Acusensus Limited
+61 408 261 554
Email: investor-relations@acusensus.com

Simon Hinsley
Investor and Media Relations
+61 401 809 653
Email: simon@nwrcommunications.com.au

This announcement is authorised by the Board of Acusensus Limited.

⁴ The timetable is indicative only and subject to variation. The Company reserves the right to alter the timetable at its discretion and without notice, subject to the ASX Listing Rules, the Corporations Act and other applicable law. All times refer to Sydney, Australia time unless denoted otherwise.

About Acusensus

Acusensus is a technology company that was founded in 2018 with a mission to design and develop artificial intelligence enabled road safety solutions. Collaborating with governments and commercial stakeholders to tackle distracted driving globally is Acusensus' first priority. Acusensus has pioneered intelligent solutions that provide anywhere, anytime digital evidence that can be used in conjunction with law enforcement to drive behavioural change and improve road safety. Acusensus technology is used to detect and provide prosecutable evidence of distracted driving (mobile phone use), seatbelt compliance, speeding, railway crossing compliance and the monitoring of vehicles of interest.

Leveraging AI and sensing expertise, Acusensus also provides technology that protects workers in live traffic environments. The Forsite by Acusensus road worker safety system integrates roadside sensors, connected wearables and real time analytics to give crews early warning of approaching vehicle risks, delivering the vital seconds needed to avoid harm while generating data that helps make worksites safer over time.

Acusensus listed on the Australian Securities Exchange in January 2023. Acusensus is headquartered in Melbourne, Australia, with offices also in Sydney, Brisbane, Perth, Auckland (New Zealand), Wellington (New Zealand), Christchurch (New Zealand), London (United Kingdom) and Las Vegas (United States).

Important information

This announcement may not be distributed or released in the United States or to US persons.

The New Shares to be offered and sold in the Placement have not been, and will not be, registered under the US Securities Act of 1933, as amended (US Securities Act), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares to be offered and sold in the Placement may not be offered or sold, directly or indirectly, in the United States, unless they are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act and any other applicable US state securities laws.